Challenges in initiating and conducting personalized cancer therapy trials: Perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1791-1798

  Rodon, Jordi ^a   Soria, J C ^b   Berger, R ^c   Batist, G ^d,e   Tsimberidou, A ^f   Bresson, C ^g   Lee, J J ^f   Rubin, E ^h   Onn, A ^c   Schilsky, R L ⁱ   Miller, W H ^d,e   Eggermont, A M ^b   Mendelsohn, J ^f   Lazar, V ^b   Kurzrock, R ^j  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SHEBA MEDICAL CENTER   (Israel)

^d MCGILL UNIVERSITY   (Canada)

^e Quebec Consortium de Recherche en Oncologie Clinique   (Canada)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g WIN Consortium   (France)

^h BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

ⁱ AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^j UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

Biomarker; Clinical trials; Personalized cancer therapy

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER THERAPY; CLINICAL RESEARCH; FUNDING; GENOMICS; GOVERNMENT REGULATION; HUMAN; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; OFF LABEL DRUG USE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STUDY DESIGN; TRANSCRIPTOMICS; CANADA; CLINICAL TRIAL (TOPIC); ECONOMICS; FRANCE; GENE EXPRESSION PROFILING; ISRAEL; LEGISLATION AND JURISPRUDENCE; METABOLISM; NEOPLASMS; PROCEDURES; PROSPECTIVE STUDY; SPAIN; SUPPLY AND DISTRIBUTION; UNITED STATES;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CANADA; CLINICAL TRIALS AS TOPIC; FRANCE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; ISRAEL; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; PROSPECTIVE STUDIES; SPAIN; UNITED STATES;

EID: 84931841428     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv191     Document Type: Article

References (40)

1. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
2. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-1901.
3. Janku F, Hong DS, Fu S et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014; 6: 377-387.
4. Janku F, Wheler JJ, Westin SN et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-782.
5. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
6. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
7. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
8. Tsimberidou AM, Iskander NG, Hong DS et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18: 6373-6383.
9. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol 2009; 27: 328-333.
10. Ciriello G, Miller ML, Aksoy BA et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-1133.
11. Munoz J, Swanton C, Kurzrock R. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book 2013; 127-134.
12. Network CGAR, Weinstein JN, Collisson EA et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113-1120.
13. Vucic EA, Thu KL, Robison K et al. Translating cancer 'omics' to improved outcomes. Genome Res 2012; 22: 188-195.
14. Soria JC, Tsimberidou A, Kurzrock R et al. WINTHER: a study to select rational therapeutics based on the analysis of tumor and matched normal tissue biopsies in subjects with advanced malignancies. Ann Oncol 2013; 24(Suppl 1): i7-i17.
15. The Worldwide Innovative Networking (WIN) Consortium; http://www.winconsortium.org (2 May 2015, date last accessed).
16. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
17. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
18. Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol 2013; 31: 1874-1884.
19. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 2011; 29: 1236-1238.
20. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013; 31: 1815-1824.
21. Roychowdhury S, Iyer MK, Robinson DR et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra121.
22. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
23. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
24. Wheler JJ, Parker BA, Lee JJ et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget 2014; 5: 2349-2354.
25. Janku F, Wheler JJ, Naing A et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012; 3: 1566-1575.
26. De Mattos-Arruda L, Rodon J. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist 2013; 18: 1180-1188.
27. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013; 31: 1834-1841.
28. Von Hoff DD, Stephenson JJ, Jr, Rosen P et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
29. Lazar V, Suo C, Orear C et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics 2013; 6: 53.
30. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
31. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012; 9: 542-548.
32. Mendelsohn J, Tursz T, Schilsky RL, Lazar V. WIN Consortium-challenges and advances. Nat Rev Clin Oncol 2011; 8: 133-134.
33. Barker AD, Sigman CC, Kelloff GJ et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97-100.
34. Conti RM, Bernstein AC, Villaflor VM et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 2013; 31: 1134-1139.
35. American Society of Clinical O. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 2006; 24: 3206-3208.
36. Harlan LC, Greene AL, Clegg LX et al. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 2005; 23: 9079-9088.
37. Wu XC, Lund MJ, Kimmick GG et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 2012; 30: 142-150.
38. National Research Council. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: The National Academies Press, 2012.
39. Kurzrock R, Kantarjian H, Stewart DJ. A cancer trial scandal and its regulatory backlash. Nat Biotechnol 2014; 32: 27-31.
40. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010; 16: 5557-5563.